申请人:NOVO NORDISK A/S
公开号:EP0511152A2
公开(公告)日:1992-10-28
Quinoxaline compounds having the formula I
wherein
R¹ is H, NO₂, CN, CF₃ or halogen, R² and R³ independently are H, CN, CF₃, halogen, C(NOH)C₁₋₆- alkyl, COR⁴ or SO₂R⁴, wherein R⁴ is C₁₋₆-alkyl, optionally substituted, or NR⁵R⁶, wherein R⁵, R⁶ independently are H, C₃₋₆-cycloalkyl, C₁₋₆-alkyl-, optionally substituted, compositions thereof and methods of preparing the compounds are described.
The compounds are useful in the treatment of indications caused by hyperactivity of the excitatory neurotransmitters.
式 I 的喹喔啉化合物
其中
R¹ 是 H、NO₂、CN、CF₃ 或卤素,R² 和 R³ 独立地是 H、CN、CF₃、卤素、C(NOH)C₁₋₆-烷基、COR⁴ 或 SO₂R⁴,其中 R⁴ 是任选取代的 C₁₋₆- 烷基、或 NR⁵R⁶,其中 R⁵、R⁶分别独立地为 H、C₃₋₆-环烷基、C₁₋₆-烷基,任选被取代;所述化合物及其组合物和制备方法。
这些化合物可用于治疗兴奋性神经递质过度活跃引起的症状。